Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 9/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638807 | 1.00 | SLC18A3 (0.83) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL2264294 | 0.98 | SLC18A3 (0.80) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| SCHEMBL9351912 | 0.94 | SLC18A3 (0.80) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Pyrrolidine SCHEMBL28789780 | 0.94 | SLC18A3 (0.87) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Benzene SCHEMBL28128069 | 0.91 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| SCHEMBL4574 | 0.91 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Hydrogen Sulfide SCHEMBL27710844 | 0.89 | SLC18A3 (0.95) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Piperazine SCHEMBL27350525 | 0.89 | SLC18A3 (0.95) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL1481633 | 0.89 | SLC18A3 (0.95) | SLC18A3SIGMAR1HTR2CHPGDKMT2A | |
| Piperidine SCHEMBL28886759 | 0.88 | SLC18A3 (0.69) | SLC18A3SIGMAR1HTR2CHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109418305-A | A kind of multipurpose pyracantha fortuneana herbicide and preparation method thereof | 张咸升 | 2019-03-05 | — | — | CN | claimed |
| WO-2006014703-A2 | HOMOPIPERDININE DERIVATIVES AS NK-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115003665-B | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2024-11-08 | — | — | CN | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1009405-A4 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1009405-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999009984-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0384843-B1 | 1-Arylsulfonyl-2-piperidinone derivatives, process and intermediates for their preparation, their pharmaceutical use and compositions containing them | ROUSSEL UCLAF (FR) | 1994-08-31 | — | — | EP | disclosed |
| EP-0384843-A2 | 1-Arylsulfonyl-2-piperidinone derivatives, process and intermediates for their preparation, their pharmaceutical use and compositions containing them | ROUSSEL-UCLAF (FR) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | SLC18A3 4364/4885SIGMAR1 4076/4885HTR2C 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.